RxDoctor Payments Data

Catherine Sever, MD

Family Medicine · Ventura, CANPI 1639233760

Payments from drug & device makers

$1,240in general payments, 2019–2025

Across 48 payments — averaging $25.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$487
  • Insulet Corporation$168
  • Dexcom, Inc.$124
  • Abbott$74
  • Tandem Diabetes Care, Inc.$64
  • Integra Lifesciences Corporation$64
  • plus $259 from 12 others

What the payments were for

  • Food & beverage$1,240100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,240 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$5,982
Medicare patients
21
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin152$164,907
OzempicSemaglutide105$125,255
TrulicityDulaglutide57$70,935
Tresiba Flextouch U-100Insulin Degludec101$59,198
JanuviaSitagliptin Phosphate43$55,810
FarxigaDapagliflozin Propanediol45$53,105
TradjentaLinagliptin25$33,598
RybelsusSemaglutide12$26,181
Tresiba Flextouch U-200Insulin Degludec26$24,782
TresibaInsulin Degludec21$16,389
FiaspInsulin Aspart (Niacinamide)12$16,307
Novolog FlexpenInsulin Aspart48$13,758
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$13,576
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$12,897
Fiasp FlextouchInsulin Aspart (Niacinamide)15$11,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Tresiba, Fiasp, Novolog$30$188,309175 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$19$83,68284 claims
AstraZenecaFarxiga$33$53,10545 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →